{"id":72505,"date":"2026-08-14T12:21:58","date_gmt":"2026-08-14T04:21:58","guid":{"rendered":"https:\/\/flcube.com\/?p=72505"},"modified":"2026-08-14T12:21:59","modified_gmt":"2026-08-14T04:21:59","slug":"xbiome-strikes-newco-style-technology-collaboration-with-biogent-therapeutics-for-ai-driven-bispecific-antibody-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=72505","title":{"rendered":"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Xbiome<\/strong>, a China\u2011based <strong>AI\u2011driven microbiome drug development company<\/strong>, announced a <strong>technology collaboration deal<\/strong> with <strong>Biogent Therapeutics (&#8220;Biogent&#8221;)<\/strong>, an <strong>AI\u2011driven innovative biotherapeutics company<\/strong>, structured in the form of a <strong>NewCo<\/strong>. Under the agreement, <strong>BioMap<\/strong> will receive up to a <strong>multi\u2011ten\u2011million\u2011dollar cash payment<\/strong> from the project collaboration, as well as a <strong>high double\u2011digit equity stake<\/strong> in the NewCo.<\/p>\n\n\n\n<h2 id=\"h-deal-snapshot\" class=\"wp-block-heading\">Deal Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Xbiome (AI\u2011driven microbiome drug development) &amp; Biogent Therapeutics (AI\u2011driven biotherapeutics)<\/td><\/tr><tr><td><strong>Deal Structure<\/strong><\/td><td>Technology collaboration in the form of a <strong>NewCo<\/strong><\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>14 Aug 2026<\/td><\/tr><tr><td><strong>Economics to BioMap<\/strong><\/td><td>Up to a multi\u2011ten\u2011million\u2011dollar cash payment; high double\u2011digit equity stake in the NewCo<\/td><\/tr><tr><td><strong>Strategic Focus<\/strong><\/td><td>Batch development of innovative bispecific and multispecific antibody pipelines for autoimmune\u2011related therapeutic areas<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-partner-profile-biogent-therapeutics\" class=\"wp-block-heading\">Partner Profile \u2013 Biogent Therapeutics<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Positioning:<\/strong> An <strong>AI\u2011powered antibody drug discovery company<\/strong><\/li>\n\n\n\n<li><strong>Incubation:<\/strong> Incubated and led by <strong>Legend Capital<\/strong>, with follow\u2011on investment from <strong>Temasek Life Sciences Accelerator<\/strong><\/li>\n\n\n\n<li><strong>Role in Collaboration:<\/strong> Leverages the <strong>AI discovery platform<\/strong> introduced from <strong>BioMap<\/strong> to continuously and batch\u2011develop innovative <strong>bispecific and multispecific antibody pipelines<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-a-new-model-from-single-asset-to-systematic-pipeline-incubation\" class=\"wp-block-heading\">A New Model \u2013 From Single Asset to Systematic Pipeline Incubation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Beyond Traditional NewCo:<\/strong> Unlike the traditional NewCo model, which centers on <strong>out\u2011licensing a single pipeline asset<\/strong>, this collaboration aims at upgrading from <strong>single\u2011molecule development to systematic pipeline incubation<\/strong>.<\/li>\n\n\n\n<li><strong>Continuous Output:<\/strong> The NewCo is designed to leverage the AI discovery platform to <strong>continuously and batch\u2011develop<\/strong> innovative <strong>bispecific and multispecific antibody<\/strong> candidates for <strong>autoimmune\u2011related therapeutic areas<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-early-execution-first-pipeline-milestones\" class=\"wp-block-heading\">Early Execution \u2013 First Pipeline Milestones<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Progress to Date:<\/strong> Biogent has completed <strong>R&amp;D and key preclinical validation<\/strong> of its first core pipelines using the AI discovery platform introduced from BioMap.<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class Asset:<\/strong> The collaboration has produced the <strong>world&#8217;s first Treg\u2011biased IL\u20112 bispecific antibody for autoimmune diseases<\/strong> \u2014 a differentiated approach aimed at selectively engaging regulatory T cells.<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform\u2011for\u2011Equity Model:<\/strong> The deal structure \u2014 cash payment plus a <strong>high double\u2011digit equity stake<\/strong> \u2014 reflects a shift from one\u2011off licensing toward sustained platform monetization through NewCo equity.<\/li>\n\n\n\n<li><strong>Autoimmune Focus:<\/strong> The emphasis on <strong>autoimmune\u2011related therapeutic areas<\/strong> aligns with one of the hottest segments in biotherapeutics, where bispecific formats and immune\u2011modulating mechanisms are in high demand.<\/li>\n\n\n\n<li><strong>Treg\u2011Biased IL\u20112 Differentiation:<\/strong> The world&#8217;s first <strong>Treg\u2011biased IL\u20112 bispecific antibody<\/strong> addresses a key challenge in IL\u20112 biology \u2014 preferential regulatory T\u2011cell activation without effector cell stimulation.<\/li>\n\n\n\n<li><strong>Repeatable Pipeline Engine:<\/strong> If the batch\u2011development model delivers, the NewCo could become a repeatable incubation engine rather than a single\u2011asset vehicle, a meaningful evolution of the NewCo playbook.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding the NewCo collaboration between Xbiome and Biogent Therapeutics, the development of bispecific and multispecific antibody pipelines, and potential clinical applications. Actual results may differ due to risks including preclinical and clinical outcomes, platform performance, and competitive dynamics in autoimmune biotherapeutics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xbiome, a China\u2011based AI\u2011driven microbiome drug development company, announced a technology collaboration deal with Biogent&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[99,4900,2966],"class_list":["post-72505","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-ai","tag-biogent-therapeutics","tag-xbiome"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Xbiome, a China\u2011based AI\u2011driven microbiome drug development company, announced a technology collaboration deal with Biogent Therapeutics (&quot;Biogent&quot;), an AI\u2011driven innovative biotherapeutics company, structured in the form of a NewCo. Under the agreement, BioMap will receive up to a multi\u2011ten\u2011million\u2011dollar cash payment from the project collaboration, as well as a high double\u2011digit equity stake in the NewCo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=72505\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development\" \/>\n<meta property=\"og:description\" content=\"Xbiome, a China\u2011based AI\u2011driven microbiome drug development company, announced a technology collaboration deal with Biogent Therapeutics (&quot;Biogent&quot;), an AI\u2011driven innovative biotherapeutics company, structured in the form of a NewCo. Under the agreement, BioMap will receive up to a multi\u2011ten\u2011million\u2011dollar cash payment from the project collaboration, as well as a high double\u2011digit equity stake in the NewCo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=72505\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-14T04:21:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-14T04:21:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72505#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72505\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development\",\"datePublished\":\"2026-08-14T04:21:58+00:00\",\"dateModified\":\"2026-08-14T04:21:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72505\"},\"wordCount\":499,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"Biogent Therapeutics\",\"Xbiome\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72505#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72505\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=72505\",\"name\":\"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-14T04:21:58+00:00\",\"dateModified\":\"2026-08-14T04:21:59+00:00\",\"description\":\"Xbiome, a China\u2011based AI\u2011driven microbiome drug development company, announced a technology collaboration deal with Biogent Therapeutics (\\\"Biogent\\\"), an AI\u2011driven innovative biotherapeutics company, structured in the form of a NewCo. Under the agreement, BioMap will receive up to a multi\u2011ten\u2011million\u2011dollar cash payment from the project collaboration, as well as a high double\u2011digit equity stake in the NewCo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72505#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=72505\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=72505#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development - Insight, China&#039;s Pharmaceutical Industry","description":"Xbiome, a China\u2011based AI\u2011driven microbiome drug development company, announced a technology collaboration deal with Biogent Therapeutics (\"Biogent\"), an AI\u2011driven innovative biotherapeutics company, structured in the form of a NewCo. Under the agreement, BioMap will receive up to a multi\u2011ten\u2011million\u2011dollar cash payment from the project collaboration, as well as a high double\u2011digit equity stake in the NewCo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=72505","og_locale":"en_US","og_type":"article","og_title":"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development","og_description":"Xbiome, a China\u2011based AI\u2011driven microbiome drug development company, announced a technology collaboration deal with Biogent Therapeutics (\"Biogent\"), an AI\u2011driven innovative biotherapeutics company, structured in the form of a NewCo. Under the agreement, BioMap will receive up to a multi\u2011ten\u2011million\u2011dollar cash payment from the project collaboration, as well as a high double\u2011digit equity stake in the NewCo.","og_url":"https:\/\/flcube.com\/?p=72505","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-14T04:21:58+00:00","article_modified_time":"2026-08-14T04:21:59+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=72505#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=72505"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development","datePublished":"2026-08-14T04:21:58+00:00","dateModified":"2026-08-14T04:21:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=72505"},"wordCount":499,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","Biogent Therapeutics","Xbiome"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=72505#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=72505","url":"https:\/\/flcube.com\/?p=72505","name":"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-14T04:21:58+00:00","dateModified":"2026-08-14T04:21:59+00:00","description":"Xbiome, a China\u2011based AI\u2011driven microbiome drug development company, announced a technology collaboration deal with Biogent Therapeutics (\"Biogent\"), an AI\u2011driven innovative biotherapeutics company, structured in the form of a NewCo. Under the agreement, BioMap will receive up to a multi\u2011ten\u2011million\u2011dollar cash payment from the project collaboration, as well as a high double\u2011digit equity stake in the NewCo.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=72505#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=72505"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=72505#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Xbiome Strikes NewCo\u2011Style Technology Collaboration with Biogent Therapeutics for AI\u2011Driven Bispecific Antibody Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72505","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=72505"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72505\/revisions"}],"predecessor-version":[{"id":72506,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/72505\/revisions\/72506"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=72505"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=72505"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=72505"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}